SENS Senseonics Holdings

Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare Conference

Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare Conference

GERMANTOWN, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel 2025 Healthcare Conference, being held in New York, NY.

2025 Stifel Healthcare Conference

Format: Fireside chat and one-on-one meetings

Date: Wednesday, November 12, 2025

Time: 4:40 pm ET

Webcast:

Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at .

About Senseonics

Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Senseonics Investor Contact

Jeremy Feffer

LifeSci Advisors





EN
10/11/2025

Underlying

SENSSenseonics Holdings

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Senseonics Holdings

 PRESS RELEASE
Free
SENS Senseonics Hold...

Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare...

Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare Conference GERMANTOWN, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel 2025 Healthcare Conference, being held in New York, NY. 2025 Stifel Healthcare Conference Format: Fireside chat and one-on-one meetingsDate: Wednesday, November 12, 2025Time: 4:40 pm...

7h / 23m 1 EN
 PRESS RELEASE
Free
SENS Senseonics Hold...

Senseonics Announces Transfer to Nasdaq Stock Exchange

Senseonics Announces Transfer to Nasdaq Stock Exchange GERMANTOWN, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, has announced that as a decision in the best interest of the Company and its stockholders, it will transfer the listing of its common stock from the NYSE American to the Nasdaq Global Select Market (“Nasdaq”), effective after the market closes on November 14, 2025. The C...

7h / 28m 1 EN
 PRESS RELEASE
Free
SENS Senseonics Hold...

Senseonics Holdings, Inc. Reports Third Quarter Financial Results

Senseonics Holdings, Inc. Reports Third Quarter Financial Results Generated Q3 revenue of $8.1 million, representing year-over-year growth of 90% Achieved a 160% increase in U.S. new patient starts over prior year Planning for the transition of CGM commercial responsibility from Ascensia Diabetes Care back to Senseonics GERMANTOWN, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, ...

November 5, 2025 1 EN
 PRESS RELEASE
Free
SENS Senseonics Hold...

Senseonics Holdings, Inc. Schedules Third Quarter 2025 Earnings Releas...

Senseonics Holdings, Inc. Schedules Third Quarter 2025 Earnings Release and Conference Call for November 5, 2025 at 4:30 P.M. Eastern Time GERMANTOWN, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2025 financial results after market close on Wednesday, November 5, 2025. Management will hold a conference call to review the...

October 22, 2025 1 EN
 PRESS RELEASE
Free
SENS Senseonics Hold...

Senseonics Announces Preliminary Unaudited Revenue for Third Quarter 2...

Senseonics Announces Preliminary Unaudited Revenue for Third Quarter 2025 and Provides Business Update Preliminary unaudited revenue of $8.1 million for Q3 2025 Generated record quarterly new patient starts in Q3 2025 Established reverse stock split ratio of 1:20, anticipated to be effective October 17, 2025 GERMANTOWN, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announc...

October 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch